SLOUGH, England, December 14 /PRNewswire/ -- Reckitt Benckiser, the manufacturer of Nurofen Plus, has been made aware of the death of a woman earlier this year from acute renal failure who, prior to her death, was taking large quantities of Nurofen Plus (in excess of 48 tablets) daily. This far exceeds the recommended and approved doses (a maximum of six tablets daily).

A Reckitt Benckiser spokesperson comments, "We offer our sincere sympathy to the Docherty family for their tragic loss. However, Reckitt Benckiser would like to reassure consumers that Nurofen Plus, and all other products in the Nurofen range, are safe and effective when taken in accordance with the pack instructions, and used to effectively relieve pain by millions of people every day."

The Nurofen Plus labelling clearly states patients should not exceed six tablets in 24 hours and to see their doctor or pharmacist if they need to take it for longer than three days. All over-the-counter (OTC) medicines, including Nurofen Plus, are regulated by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA). In common with other P-licenced medicines, Nurofen Plus is only available from pharmacies and is sold under the strict supervision of qualified pharmacists who can advise on its correct use.

Reckitt Benckiser takes the health of its customers very seriously and would like to reiterate that care should always be taken when using OTC medicines. As with all medicines it is important to fully read the pack leaflet labelling which clearly lists the conditions each product is suitable to treat, the cautions for use, the recommended dose, directions for use and when it should not be taken. If in any doubt, patients should ask a pharmacist or their doctor.

Issued by Virgo HEALTH PR on behalf of Reckitt Benckiser Healthcare International

For further information, please contact: Hannah O'Neill or Lisa Rodwell, Tel: +44(0)7799-108818 / +44(0)7976-735547 / Email: hannah.oneill@virgohealthpr.com